InvestorsHub Logo
Followers 24
Posts 3015
Boards Moderated 0
Alias Born 01/18/2009

Re: None

Tuesday, 12/21/2010 8:55:48 AM

Tuesday, December 21, 2010 8:55:48 AM

Post# of 10237
Sunesis Launches Phase 3 VALOR Trial of Vosaroxin in AML

Date : 12/21/2010 @ 8:00AM
Source : MarketWire
Stock : Sunesis Pharmaceuticals (SNSS)

http://ih.advfn.com/p.php?pid=nmona&article=45739543

unesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the first patient has been randomized and dosed with blinded study treatment in its pivotal Phase 3 VALOR trial of vosaroxin, the company's lead drug candidate, in combination with cytarabine in patients with first relapsed or refractory acute myeloid leukemia (AML). The VALOR trial is a multinational, randomized, double-blind, placebo-controlled, pivotal trial which is expected to enroll 450 evaluable patients at leading sites in the U.S., Canada, Europe, Australia and New Zealand.

...

posts are IMHO // either news - with LINK

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.